An Act establishing a commission to study maximum allowable costs lists
Take action
Record your position on this measure.
Create an account to take a stance, submit a written position, or contact your legislator.
Progress
Where this bill stands in the legislative process.
- Introduced
- Passed House
- Passed Senate
- To Governor
- Became Law
Overview
This bill establishes a commission to investigate how health plans and pharmaceutical benefit managers determine the maximum amount they will pay for prescription drugs. The commission will include members of the General Court and will examine ‘maximum allowable costs lists’ used in this process. The goal is to understand and potentially improve transparency and affordability in prescription drug pricing.
Key provisions
- Create a commission to study maximum allowable costs lists.
- Include members of the General Court on the commission.
- Examine how payers and pharmaceutical benefit managers use these lists.
- Investigate the impact of these lists on prescription drug pricing.
- The commission will hold a hearing on October 1, 2025.
Who is affected
- Health plans
- Pharmaceutical benefit managers
- Prescription drug users
- The General Court
- Patients
Notable changes
- The bill aims to increase transparency in prescription drug pricing.
- It focuses on ‘maximum allowable costs lists’ – a specific mechanism used to determine drug prices.
- The commission’s findings could lead to policy changes related to drug pricing.
Bill text
Read the latest version inline or switch to a previous version.
Text extraction is in progress. View the official source.
Sponsors
Official sponsors from legislative records.
5 on record
Primary sponsor
Bradley H. Jones Jr.
Cosponsors
Bradley H. Jones Jr.
Kimberly N. Ferguson
Arguments
Reasons offered for and against this legislation.
Arguments in favor
No arguments in favor have been submitted.
Submit yoursArguments opposed
No arguments opposed have been submitted.
Submit yours